minimal Common Oncology Data Elements (mCODE) Implementation Guide
4.0.0-ballot - STU4 Ballot United States of America flag

This page is part of the HL7 FHIR Implementation Guide: minimal Common Oncology Data Elements (mCODE) Release 1 - US Realm | STU1 (v4.0.0-ballot: STU4 Ballot 1) based on FHIR (HL7® FHIR® Standard) R4. The current version which supersedes this version is 3.0.0. For a full list of available versions, see the Directory of published versions

: cancer-related-medication-admin-idarubicin-brian-l - JSON Representation

Raw json | Download


{
  "resourceType" : "MedicationAdministration",
  "id" : "cancer-related-medication-admin-idarubicin-brian-l",
  "meta" : {
    "profile" : [
      🔗 "http://hl7.org/fhir/us/mcode/StructureDefinition/mcode-cancer-related-medication-administration"
    ]
  },
  "text" : {
    "status" : "extensions",
    "div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p><b>Generated Narrative: MedicationAdministration</b><a name=\"cancer-related-medication-admin-idarubicin-brian-l\"> </a><a name=\"hccancer-related-medication-admin-idarubicin-brian-l\"> </a></p><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\">Resource MedicationAdministration &quot;cancer-related-medication-admin-idarubicin-brian-l&quot; </p><p style=\"margin-bottom: 0px\">Profile: <a href=\"StructureDefinition-mcode-cancer-related-medication-administration.html\">Cancer-Related Medication Administration Profile</a></p></div><p><b>Normalization Basis Extension</b>: Body surface area (observable entity) <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (<a href=\"https://browser.ihtsdotools.org/\">SNOMED CT</a>#301898006)</span></p><p><b>status</b>: completed</p><p><b>category</b>: Inpatient <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (<a href=\"http://terminology.hl7.org/5.3.0/CodeSystem-medicationrequest-category.html\">MedicationRequest Category Codes</a>#inpatient)</span></p><p><b>medication</b>: IDArubicin <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (<a href=\"http://terminology.hl7.org/5.3.0/CodeSystem-v3-rxNorm.html\">RxNorm</a>#5650)</span></p><p><b>subject</b>: <a href=\"Patient-cancer-patient-brian-l.html\">Patient/cancer-patient-brian-l</a> &quot; L&quot;</p><p><b>effective</b>: 2024-01-09</p><h3>Performers</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Actor</b></td></tr><tr><td style=\"display: none\">*</td><td><a href=\"Practitioner-us-core-practitioner-nancy-oncology-nurse.html\">Practitioner/us-core-practitioner-nancy-oncology-nurse</a> &quot; NURSE&quot;</td></tr></table><p><b>reasonReference</b>: <a href=\"Condition-primary-cancer-condition-brian-l.html\">Condition/primary-cancer-condition-brian-l</a></p><p><b>request</b>: <a href=\"MedicationRequest-cancer-related-medication-request-idarubicin-brian-l.html\">MedicationRequest/cancer-related-medication-request-idarubicin-brian-l</a></p><p><b>note</b>: IDArubicin (c), 5.4mg. Patient tolerated infusion without side effects. (By Practitioner/us-core-practitioner-nancy-oncology-nurse @2024-01-09)</p><h3>Dosages</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Route</b></td><td><b>Dose</b></td></tr><tr><td style=\"display: none\">*</td><td>Intravenous route (qualifier value) <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (<a href=\"https://browser.ihtsdotools.org/\">SNOMED CT</a>#47625008)</span></td><td>5.4 mg<span style=\"background: LightGoldenRodYellow\"> (Details: UCUM code mg = 'mg')</span></td></tr></table></div>"
  },
  "extension" : [
    {
      "url" : "http://hl7.org/fhir/us/mcode/StructureDefinition/mcode-normalization-basis",
      "valueCodeableConcept" : {
        "coding" : [
          {
            "system" : "http://snomed.info/sct",
            "code" : "301898006",
            "display" : "Body surface area (observable entity)"
          }
        ]
      }
    }
  ],
  "status" : "completed",
  "category" : {
    "coding" : [
      {
        "system" : "http://terminology.hl7.org/CodeSystem/medicationrequest-category",
        "code" : "inpatient"
      }
    ]
  },
  "medicationCodeableConcept" : {
    "coding" : [
      {
        "system" : "http://www.nlm.nih.gov/research/umls/rxnorm",
        "code" : "5650",
        "display" : "IDArubicin"
      }
    ]
  },
  "subject" : {
    🔗 "reference" : "Patient/cancer-patient-brian-l"
  },
  "effectiveDateTime" : "2024-01-09",
  "performer" : [
    {
      "actor" : {
        🔗 "reference" : "Practitioner/us-core-practitioner-nancy-oncology-nurse"
      }
    }
  ],
  "reasonReference" : [
    {
      🔗 "reference" : "Condition/primary-cancer-condition-brian-l"
    }
  ],
  "request" : {
    🔗 "reference" : "MedicationRequest/cancer-related-medication-request-idarubicin-brian-l"
  },
  "note" : [
    {
      "authorReference" : {
        🔗 "reference" : "Practitioner/us-core-practitioner-nancy-oncology-nurse"
      },
      "time" : "2024-01-09",
      "text" : "IDArubicin (c), 5.4mg. Patient tolerated infusion without side effects."
    }
  ],
  "dosage" : {
    "route" : {
      "coding" : [
        {
          "system" : "http://snomed.info/sct",
          "code" : "47625008",
          "display" : "Intravenous route (qualifier value)"
        }
      ]
    },
    "dose" : {
      "value" : 5.4,
      "unit" : "mg",
      "system" : "http://unitsofmeasure.org",
      "code" : "mg"
    }
  }
}